Detalhe da pesquisa
1.
Safety, pharmacokinetics and pharmacodynamics of BI 655064 in phase 1 clinical trials in healthy Chinese and Japanese subjects.
Br J Clin Pharmacol
; 87(4): 2000-2013, 2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33047859
2.
Safety, pharmacokinetics and pharmacodynamics of BI 705564, a highly selective, covalent inhibitor of Bruton's tyrosine kinase, in Phase I clinical trials in healthy volunteers.
Br J Clin Pharmacol
; 87(4): 1824-1838, 2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-32986868
3.
Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis.
N Engl J Med
; 376(16): 1551-1560, 2017 04 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-28423301
4.
Psoriatic skin molecular and histopathologic profiles after treatment with risankizumab versus ustekinumab.
J Allergy Clin Immunol
; 143(6): 2158-2169, 2019 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-30578873
5.
Effects of BI 655064, an antagonistic anti-CD40 antibody, on clinical and biomarker variables in patients with active rheumatoid arthritis: a randomised, double-blind, placebo-controlled, phase IIa study.
Ann Rheum Dis
; 78(6): 754-760, 2019 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-30902820
6.
Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study.
Lancet
; 389(10080): 1699-1709, 2017 04 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-28411872
7.
Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study.
Ann Rheum Dis
; 77(9): 1295-1302, 2018 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-29945918
8.
Safety, pharmacokinetics and pharmacodynamics of single rising doses of BI 655064, an antagonistic anti-CD40 antibody in healthy subjects: a potential novel treatment for autoimmune diseases.
Eur J Clin Pharmacol
; 74(2): 161-169, 2018 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-29127458
9.
Inhibition of the Interleukin-36 Pathway for the Treatment of Generalized Pustular Psoriasis.
N Engl J Med
; 380(10): 981-983, 2019 03 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-30855749
10.
Long-Term Efficacy and Safety of Risankizumab in Patients with Active Psoriatic Arthritis: Results from a 76-Week Phase 2 Randomized Trial.
Rheumatol Ther
; 9(5): 1361-1375, 2022 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-35931879
11.
Spesolimab, an Anti-Interleukin-36 Receptor Antibody, in Patients with Palmoplantar Pustulosis: Results of a Phase IIa, Multicenter, Double-Blind, Randomized, Placebo-Controlled Pilot Study.
Dermatol Ther (Heidelb)
; 11(2): 571-585, 2021 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-33661508
12.
Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Rising Doses of BI 655064, an Antagonistic Anti-CD40 Antibody, in Healthy Subjects: A Potential Novel Treatment for Autoimmune Diseases.
J Clin Pharmacol
; 58(12): 1566-1577, 2018 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-30113724
13.
Selective IL-23 Inhibition by Risankizumab Modulates the Molecular Profile in the Colon and Ileum of Patients With Active Crohn's Disease: Results From a Randomised Phase II Biopsy Sub-study.
J Crohns Colitis
; 12(10): 1170-1179, 2018 Nov 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-30032288
14.
Risankizumab in patients with moderate to severe Crohn's disease: an open-label extension study.
Lancet Gastroenterol Hepatol
; 3(10): 671-680, 2018 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-30056030
15.
Reactivity of dog sera to whole-cell or recombinant antigens of Borrelia burgdorferi by ELISA and immunoblot analysis.
J Med Microbiol
; 50(10): 889-895, 2001 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-11599738